About this Research Topic
Minimally invasive urologic surgery has undergone a revolutionary transformation in recent years, driven by technological advancements and a growing emphasis on patient-centred care. This has led to the emergence of new minimally invasive surgical techniques (MISTs) for the treatment of benign and malignant urologic conditions, as well as the adoption of novel technologies such as lasers and robotic systems.
Laparoscopy and robotic surgery have become the cornerstone of pelvic and upper tract oncology, providing a less invasive alternative to traditional open surgery. Robotic prostatectomy, brachytherapy, radiotherapy, cryotherapy, and high-intensity focused ultrasound (HIFU) are now commonly used for the treatment of prostate cancer. Robotic partial nephrectomy and cryotherapy have similarly transformed the management of renal cancer, while robotic cystectomy and en-bloc resection of bladder cancer have emerged as promising treatments for muscle-invasive bladder cancer.
For benign urologic conditions, MISTs have given new meaning to the surgical treatment of benign prostate hyperplasia (BPH). Laser treatments including Holmium, Thulium and GreenLight, as well as water-based treatments such as Rezum and Aquablation, and other minimally invasive procedures like prostate artery embolization (PAE), TIND and Urolift have been increasingly used. Additionally, there is an increasing emphasis on the role of suction in endourological procedures, while the use of Thulium fiber laser (TFL), Moses technology, and small disposable ureteroscopes have helped to expand the boundaries of ureteroscopy (URS) and percutaneous nephrolithotomy (PCNL) procedures.
These advancements have led to improvements in patient's quality of life (QoL), shorter hospital stays, and reduced complication rates. Additionally, MISTs have expanded the indications for surgery and made it possible to offer surgical treatment to a wider range of patients. the role of minimally invasive urologic surgery has expanded greatly in recent years, with new technologies and techniques driving significant improvements in patient outcomes. The adoption of these innovations has enabled urologic surgeons to offer patients more personalized and effective care, with fewer complications and shorter recovery times. As the field continues to evolve, it will be important to carefully evaluate the efficacy and safety of new techniques and technologies to ensure that patients continue to receive the highest quality of care.
Aims and Scope of Research Topic:
- Minimally Invasive Surgery
- Robotic Surgery
- Laparoscopy
- Endourology
- Laser Treatments
- Benign Prostate Hyperplasia (BPH)
- Ureteroscopy (URS)
- Percutaneous Nephrolithotomy (PCNL)
- Shockwave lithotripsy (SWL)
- Robotic Surgery
- Prostate Cancer
- Bladder Cancer
- Laser
- Innovation and Training
- Technology and AI
Laparoscopy and robotic surgery have become the cornerstone of pelvic and upper tract oncology, providing a less invasive alternative to traditional open surgery. Robotic prostatectomy, brachytherapy, radiotherapy, cryotherapy, and high-intensity focused ultrasound (HIFU) are now commonly used for the treatment of prostate cancer. Robotic partial nephrectomy and cryotherapy have similarly transformed the management of renal cancer, while robotic cystectomy and en-bloc resection of bladder cancer have emerged as promising treatments for muscle-invasive bladder cancer.
For benign urologic conditions, MISTs have given new meaning to the surgical treatment of benign prostate hyperplasia (BPH). Laser treatments including Holmium, Thulium and GreenLight, as well as water-based treatments such as Rezum and Aquablation, and other minimally invasive procedures like prostate artery embolization (PAE), TIND and Urolift have been increasingly used. Additionally, there is an increasing emphasis on the role of suction in endourological procedures, while the use of Thulium fiber laser (TFL), Moses technology, and small disposable ureteroscopes have helped to expand the boundaries of ureteroscopy (URS) and percutaneous nephrolithotomy (PCNL) procedures.
These advancements have led to improvements in patient's quality of life (QoL), shorter hospital stays, and reduced complication rates. Additionally, MISTs have expanded the indications for surgery and made it possible to offer surgical treatment to a wider range of patients. the role of minimally invasive urologic surgery has expanded greatly in recent years, with new technologies and techniques driving significant improvements in patient outcomes. The adoption of these innovations has enabled urologic surgeons to offer patients more personalized and effective care, with fewer complications and shorter recovery times. As the field continues to evolve, it will be important to carefully evaluate the efficacy and safety of new techniques and technologies to ensure that patients continue to receive the highest quality of care.
Aims and Scope of Research Topic:
- Minimally Invasive Surgery
- Robotic Surgery
- Laparoscopy
- Endourology
- Laser Treatments
- Benign Prostate Hyperplasia (BPH)
- Ureteroscopy (URS)
- Percutaneous Nephrolithotomy (PCNL)
- Shockwave lithotripsy (SWL)
- Robotic Surgery
- Prostate Cancer
- Bladder Cancer
- Laser
- Innovation and Training
- Technology and AI
Keywords: Urologic Surgery, Minimally Invasive, treatment, Laparoscopy, Robotic Surgery
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
